Cancer Letters
Volume 291, Issue 2 , Pages 237-245 , 28 May 2010

Histone acetyltransferase p300 is a coactivator for transcription factor REL and is C-terminally truncated in the human diffuse large B-cell lymphoma cell line RC-K8

Received 13 August 2009 ,Revised 22 October 2009 ,Accepted 26 October 2009.

References 

  1. Gilmore TD, Kalaitzidis D, Liang M-C, Starczynowski DT. The c-Rel transcription factor and B-cell proliferation: a deal with the devil. Oncogene. 2004;23:2275–2286
  2. Köntgen F, Grumont RJ, Strasser A, Metcalf D, Li R, Tarlinton D, et al. Mice lacking the c-REL proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. Genes Dev. 1995;9:1965–1977
  3. Starczynowski DT, Trautmann H, Pott C, Harder L, Arnold N, Africa JA, et al. Mutation of an IKK phosphorylation site within the transactivation domain of REL in two patients with B-cell lymphoma enhances REL’s in vitro transforming activity. Oncogene. 2007;26:1694–2685
  4. Gilmore TD, Cormier C, Jean-Jacques J, Gapuzan M-E. Malignant transformation of primary chicken spleen cells by human transcription factor c-Rel. Oncogene. 2001;20:7098–7103
  5. Kalaitzidis D, Davis RE, Rosenwald A, Staudt LM, Gilmore TD. The human B-cell lymphoma cell line RC-K8 has multiple genetic alterations that dysregulate the Rel/NF-κB signal transduction pathway. Oncogene. 2002;21:8759–8768
  6. Martin AG, San-Antonio B, Fresno M. Regulation of nuclear factor κB transactivation: implications of phosphatidylinositol 3-kinase and protein kinase Cζ in c-Rel activation by tumor necrosis factor α. J. Biol. Chem. 2001;276:15840–15849
  7. Starczynowski DT, Reynolds JG, Gilmore TD. Deletion of either C-terminal transactivation subdomain enhances the in vitro transforming activity of human transcription factor REL in chicken spleen cells. Oncogene. 2003;22:6928–6936
  8. Carrasco D, Cheng J, Lewin A, Warr G, Yang H, Rizzo C, et al. Multiple hemopoietic defects and lymphoid hyperplasia in mice lacking the transcriptional activation domain of the c-Rel protein. J. Exp. Med. 1998;187:973–984
  9. Iyer ND, Özdag H, Caldas C. p300/CBP and cancer. Oncogene. 2004;23:4225–4231
  10. Kalkhoven E. CBP and p300: HATs for different occasions. Biochem. Pharmacol. 2004;68:1145–1155
  11. Gerritsen ME, Williams AJ, Neish AS, Moore S, Shi Y, Collins T. CREB-binding protein/p300 are transcriptional coactivators of p65. Proc. Natl. Acad. Sci. USA. 1997;94:2927–2932
  12. Zhong H, Voll RE, Ghosh S. Phosphorylation of NF-κB p65 by PKA stimulates transcription activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol. Cell. 1998;1:661–671
  13. Ravi R, Mookerjee B, van Hensbergen Y, Bedi GC, Giordano A, El-Deiry WS, et al. p53-mediated repression of nuclear factor κB RelA via the transcriptional integrator p300. Cancer Res. 1998;58:4531–4536
  14. Sheppard K-A, Rose DW, Haque ZK, Kurokawa R, McInerney E, Westin S, et al. Transcriptional activation by NF-κB requires multiple coactivators. Mol. Cell Biol. 1999;19:6367–6378
  15. Webster GA, Perkins ND. Transcriptional cross talk between NF-κB and p53. Mol. Cell Biol. 1999;5:3485–3495
  16. Zhong H, May MJ, Jimi E, Ghosh S. The phosphorylation status of nuclear NF-κB determines its association with CBP/p300 or HDAC1. Mol. Cell. 2002;9:625–636
  17. Huang W-C, Ju T-K, Hung M-C, Chen C-C. Phosphorylation of CBP by IKKα promotes cell growth by switching the binding preference of CBP from p53 to NF-κB. Mol. Cell. 2007;26:75–87
  18. Saha RN, Jana M, Pahan K. MAPK p38 regulates transcriptional activity of NF-κB in primary human astrocytes via acetylation of p65. J. Immunol. 2007;179:7101–7109
  19. Wang J, Wang X, Hussain S, Zheng Y, Sanjabi S, Ouaaz F, et al. Distinct roles of different NF-κB subunits in regulating inflammatory and T cell stimulatory gene expression in dendritic cells. J. Immunol. 2007;178:6777–6788
  20. Sun H, Lu J, Wei L, Wang X, Xu X, Dong M, et al. Histone acetyltransferase activity of p300 enhances the activation of IL-12 p40 promoter. Mol. Immunol. 2004;41:1241–1246
  21. Yu S-H, Chiang W-C, Shih H-M, Wu K-J. Stimulation of c-Rel transcriptional activity by PKA catalytic subunit β. J. Mol. Med. 2004;82:621–628
  22. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Press; 1989;
  23. Starczynowski DT, Reynolds JG, Gilmore TD. Mutations of tumor necrosis factor α-responsive serine residues within the C-terminal transactivation domain of human transcription factor REL can enhance its in vitro transforming ability. Oncogene. 2005;24:7355–7368
  24. Garbati MR, Gilmore TD. Ser484 and Ser494 in REL are the major sites of IKK phosphorylation in vitro: evidence that IKK does not directly enhance GAL4-REL transactivation. Gene Expr. 2008;14:195–205
  25. Schreiber E, Matthias P, Müller MM, Schaffner W. Rapid detection of octamer binding proteins with ‘mini-extracts’, prepared from a small number of cells. Nucleic Acids Res. 1989;17:6419
  26. Feinberg AP, Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal. Biochem. 1983;132:6–13
  27. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402–408
  28. Kalaitzidis D, Gilmore TD. Genomic organization and expression of the rearranged REL proto-oncogene in the human B-cell lymphoma cell line RC-K8. Genes Chromosomes Cancer. 2002;34:129–135
  29. Lu D, Thompson JD, Gorski GK, Rice NR, Mayer MG, Yunis JJ. Alterations at the rel locus in human lymphoma. Oncogene. 1991;6:1235–1241
  30. Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, et al. Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma. Nature. 2009;459:717–721
  31. Fan Y, Gélinas C. An optimal range of transcription potency is necessary for efficient cell transformation by c-Rel to ensure optimal nuclear localization and gene-specific activation. Oncogene. 2007;26:4033–4038
  32. Bash J, Zong WX, Gélinas C. c-Rel arrests proliferation of HeLa cells and affects critical cell regulators of the G1/S-phase transition. Mol. Cell Biol. 1997;17:6526–6536
  33. Wertz IE, O’Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S, et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signaling. Nature. 2004;430:694–699
  34. Lin S-C, Chung JY, Lamothe B, Rajashankar K, Lu M, Lo Y-C, et al. Molecular basis for the unique deubiquitination activity of the NF-κB inhibitor A20. J. Mol. Biol. 2008;376:526–540
  35. Walsh MC, Kim GK, Maurizio PL, Molnar EE, Choi Y. TRAF6 autoubiquitination-independent activation of the NFκB and MAPK pathways in response to IL-1 and RANKL. PLoS One. 2009;3:e4064
  36. Bordoli L, Hüsser S, Lüthi U, Netsch M, Osmani H, Eckner R. Functional analysis of the p300 acetyltransferase domain: the PHD finger of p300 but not of CBP is dispensable for enzymatic activity. Nucleic Acids Res. 2001;29:4462–4471
  37. Liu C, Lu J, Tan J, Li L, Huang B. Human interleukin-5 expression is synergistically regulated by histone acetyltransferase CBP/p300 and transcription factors C/EBP, NF-AT and AP-1. Cytokine. 2004;27:93–100
  38. Gayther SA, Batley SJ, Linger L, Bannister A, Thorpe K, Chin S-F, et al. Mutations truncating the EP300 acetylase in human cancers. Nat. Genet. 2000;24:300–303
  39. Bryan EJ, Jokubaitis VJ, Chamberlain NL, Baxter SW, Dawson E, Choong DYH, et al. Mutation analysis of EP300 in colon, breast and ovarian carcinomas. Int. J. Cancer. 2002;102:137–141
  40. Suganuma T, Kawabata M, Ohshima T, Ikeda M-A. Growth suppression of human carcinoma cells by reintroduction of the p300 coactivator. Proc. Natl. Acad. Sci. USA. 2008;99:13073–13078
  41. Rebel VI, Kung AL, Tanner EA, Yang H, Bronson RT, Livingston DM. Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal. Proc. Natl. Acad. Sci. USA. 2002;99:14789–14794
  42. Laï JL, Jouet JP, Bauters F, Deminatti M. Chronic myelogenous leukemia with translocation (8:22): report of a new case. Cancer Genet. Cytogenet. 1985;17:365–366
  43. Ida K, Kitabayashi I, Taki T, Taniwaka M, Noro K, Yamamoto M, et al. Adenoviral E1A-associated protein p300 is involved in acute myeloid leukemia with t(11;22) (q23;q13). Blood. 1997;90:4699–4704
  44. Kitabayashi I, Aikawa Y, Yokoyama A, Hosoda F, Nagai M, Kakazu N, et al. Fusion of MOZ and p300 histone acetyltransferases in acute monocytic leukemia with a t(8;22)(p11;q13) chromosome translocation. Leukemia. 2001;15:89–94

PII: S0304-3835(09)00656-9

doi: 10.1016/j.canlet.2009.10.018

Cancer Letters
Volume 291, Issue 2 , Pages 237-245 , 28 May 2010

Article Tools

* Image Usage & Resolution